
# Pharmacopeia Standards-Global Teva R&D Perspective


Tal Hadad-Avadyayev, Associate Director, Head of Analytical Resources R&D - Teva IL


March 2019, Strasbourg



teva











## Primary standards – mandatory requirements

#### Characterization data and documentation

Full characterization data should be available. This includes: structure elucidation by <sup>1</sup>H-NMR, <sup>13</sup>C-NMR, UV spectrum, LCMS analysis, etc. The related spectra and chromatograms should be provided.

#### Defined potency

The potency of the primary standard should be calculated and stated in the CoA.

#### Impurities analysis

LODs and LOQs of all known impurities, down to penultimate step, for the API batch used as reference standard are requested.


Impurities response factors


Response factors of all impurities present at or above their reporting thresholds are requested.

Methods and methods validation reports


Methods and their validation data for quantitative instrumental analyses, such as: chromatography, water by KF, etc. are requested.


teva







teva






















## **Case Study**

Case Study: Elution order of cis and trans isomers mistakenly assigned

Impact: Investigation was opened in Teva which increased workload in the lab challenging the release timelines

### Findings:


- 1. USP declared the cis/trans isomers order of elution based on the supplier's data without verifying the supplier actual data or proving it at an USP lab.
- 2. Teva ordered the syntheses and the full characterization of the isomers (due to different ratio of the cis/trans isomers obtained in Teva QC lab vs. USP product profile).
- 3. Based on the characterization data provided by Teva, USP concluded that the monograph erroneously stated the cis and trans isomers retention times


teva


#### Conclusions:


- 1. Teva recognizes the immediate reply and data verification by USP.
- 2. We recommend to verify the data supplied in order to keep the credibility level of USP.


#### | 20 |






























|        |   | alpha | beta | gamma | delta | Ar        | Ar    | Ar    | Ar    | co    | HMBC  |        |
|--------|---|-------|------|-------|-------|-----------|-------|-------|-------|-------|-------|--------|
| Tyr(1) | С | 54,5  | 36,3 |       |       | 125,9     | 130,7 | 115,7 | 154,9 | 169,4 | 4,14  | to Ala |
|        | н | 4,01  | 3,10 |       |       |           | 7,10  | 6,88  |       |       | 4,01  |        |
|        |   |       | 3,00 |       |       |           |       |       |       |       | 3,10  |        |
|        |   |       |      |       |       |           |       |       |       |       | 3,00  |        |
| Ala    | С | 49,3  | 16,1 |       |       |           |       |       |       | 174,4 | 4,61  | to Phe |
|        | н | 4,14  | 0,90 |       |       |           |       |       |       |       | 4,14  |        |
|        |   |       |      |       |       |           |       |       |       |       | 0,90  |        |
| Phe    | С | 54,8  | 36,9 |       |       | 136,3     | 129,1 | 128,6 | 128,6 | 173,5 | 4,61  |        |
|        | н | 4,61  | 3,16 |       |       |           | 7,24  | 7,36  | 7,36  |       | 3,86  | to Gly |
|        |   |       | 2,89 |       |       |           |       |       |       |       | 3,77  | to Gly |
|        |   |       |      |       |       |           |       |       |       |       | 3,16  |        |
|        |   |       |      |       |       |           |       |       |       |       | 2,89  |        |
| Gly    | С | 42,1  |      |       |       |           |       |       |       | 170,5 | 4,85  | to Tyr |
|        | н | 3,86  |      |       |       |           |       |       |       |       | 3,86  |        |
|        |   | 3,77  |      |       |       |           |       |       |       |       | 3,77  |        |
| Tyr(2) | С | 52,9  | 35,5 |       |       | 127,8     | 130,7 | 115,4 | 154,4 | 171,5 | 4,85  |        |
|        | н | 4,85  | 3,10 |       |       |           | 7,17  | 6,86  |       |       | 4,49  | to Pro |
|        |   |       | 2,87 |       |       |           |       |       |       |       | 3,10  |        |
|        |   |       |      |       |       |           |       |       |       |       | 2,87  |        |
| Pro    | С | 60,7  | 29,0 | 24,4  | 47,7  |           |       |       |       | 174,1 | 4,49  |        |
|        | н | 4,49  | 2,31 | 2,03  | 3,82  |           |       |       |       |       | 4,42? | to Ser |
|        |   |       | 1,98 |       | 3,57  |           |       |       |       |       | 2,31  |        |
|        |   |       |      |       |       |           |       |       |       |       | 1,98  |        |
| Ser(1) | С | 55,3  | 61,0 |       |       |           |       |       |       | 174,3 | 4,42  |        |
|        | н | 4,42  | 3,88 |       |       |           |       |       |       |       | 3,88  |        |
|        |   |       |      |       |       | posium, M |       |       |       |       |       | 1      |














|          | TITRATIO            | N            | HPLC         |             | qNMR#             |          |
|----------|---------------------|--------------|--------------|-------------|-------------------|----------|
|          | PhEur<br>01/2008:00 | 690          | QC<br>method |             | Generic<br>method |          |
|          |                     |              |              |             |                   |          |
| Batch    | Assay, %            | SD (n=3)     | Assay, %     | SD (n=2)    | Assay, %          | SD (n=3) |
| 1        | 99,5                | 0,1          | 99,6         | 0,1         | 99,6              | 0,9      |
| 2        | 99,5                | 0,1          | 99,6         | 0,0         | 100,1             | 0,4      |
| 3        | 99,5                | 0,1          | 99,5         | 0,0         | 100,0             | 1,0      |
| 4        | 99,5                | 0,1          | 100,0        | 0,4         | 99,8              | 0,5      |
| Ref. std | -                   | -            |              | -           | 99,5              | 0,3      |
| #        | aNMR assa           | v calculated | assuming [t  | erbutalin * | 1/2 H SO 1        |          |





















| Why NMR?   |   |
|--|---|
| <ul> <li>Positive</li> <li>Quick sample preparation</li> <li>Automated analysis</li> <li>Non-destructive (samples may be re-used)</li> <li>Much information in a single analysis</li> <li>Quantitative – equal response for any compound</li> <li>Robust, a minimum of calibration and maintenance required</li> <li>Many different NMR-experiments available in order to obtain qualitative and/or quantitative data</li> </ul> | <ul> <li>Negative</li> <li>Expensive equipment</li> <li>Trained operators required</li> <li>Sometimes complicated data<br/>interpretation</li> <li>Need for regular N<sub>2</sub>(I) and He(I)<br/>refills</li> <li>Equipment may require a dedicated<br/>room</li> </ul> |
| IRSS Symposiu  | ım, March 2019 24   |
| WEDISH MEDICAL PRODUCTS AGENCY   |   |









| Fermen     | tation and Semisythetic Synthesis   | Pharma<br>Consulting & Services |
|------------|---|---------------------------------|
| Ferr       | nentation manufacturing processes   |                                 |
| 0          | biological systems are involved   |                                 |
| 0          | processes less stable than chemical raction                                     | ns                              |
| 0          | complex mixtures of related substances m  | ay be formed                    |
| 0          | degradation products, by-products, interm having biological activity may result | nediates                        |
| Ser        | mi-synthetic manufacturing processes  |                                 |
| 0          | fermentation products are starting mater  | ials                            |
| 0          | subsequent chemical reactions   |                                 |
| 13.03.2019 | Dr. Bernhard Wolf   | 4                               |


| Manufacturnig Proces   | sses of Antibiotics  | Pharma<br>Consulting & Services |
|------------------------|--|---------------------------------|
| Proc                   | luction of Antibiotics   |                                 |
| 0<br>0<br>0<br>0<br>0  | Penicillins/Cephalosporins<br>Carbapenems<br>Aminoglycosides<br>Macrolides<br>Polymyxins<br>Tetracyclins |                                 |
| o<br>by Cher<br>o<br>o | mical Synthesis<br>Sulfonamids<br>Gyrase Inhibitors  |                                 |
| 13.03.2019             | Dr. Bernhard Wolf  | 5                               |


|   |  | Pharma<br>Consulting & Service |
|---|--|--------------------------------|
| Meropenem   |  |                                |
| DEFINITION  |  |                                |
| Semi-synthetic pro                                    | duct derived from a fermentation   | product, or synthetic produc   |
| RELATED SUBSTAN                                       | CES  |                                |
| Limits:<br>– unspecified impu<br>– disregard limit: C | <i>rities</i> : for each impurity, not more<br>.05 %                             | e 0.10 %                       |
| •   | hydrate produced by a fully synth<br>irities: for each impurity, 0.05 %<br>.03 % | etic process:                  |
| .2019   | Dr. Bernhard Wolf  | 6                              |

| Substance  | s for Pharmaceutical Use   | Pharma<br>Consulting & Services |
|------------|--|---------------------------------|
|            | ONTROL OF IMPURITIES IN SUBS   | TANCES                          |
| Substances | ions of the Related substances section of the<br>s for pharmaceutical use (2034), notably tho<br>, do not apply to | • • •                           |
| fermentati | on products and semi-synthetic products de   | rived therefrom.                |
|            |  |                                 |
| 13.03.2019 | Dr. Bernhard Wolf  | 7                               |


| Inresn             | olas for Impur      | ities in drug sul   | ostances (Q3A   | s) |
|--------------------|---------------------|---|---|----|
| Maximum daily dose | Reporting threshold | Identification threshold                                  | Qualification threshold                                   | ]  |
| <u>&lt;</u> 2g/day | 0.05 %              | 0.10% or 1.0 mg<br>per day intake<br>(whichever is lower) | 0.15% or 1.0 mg<br>per day intake<br>(whichever is lower) |    |
| >2g/day            | 0.03 %              | 0.05%   | 0.05%   |    |
| >2g/day            | 0.03 %              | 0.05%   | 0.05%   |    |

| EMA Guide                           | ine                     |   |   | Pharma<br>Consulting & | Services |
|-------------------------------------|-------------------------|---|---|------------------------|----------|
| (EM/                                | EMA guide<br>\/CHMP/CVM | •   | -   | corr.)                 |          |
| Guideline d                         | on setting specifica    | tions for relate                            | ed impurities in                            | antibiotics            |          |
| Guideline o<br>Active<br>substances | on setting specifica    | tions for relate<br>Fermentation,<br>single | ed impurities in<br>Fermentation,<br>family | antibiotics Peptides   |          |
| Active                              |                         | Fermentation,                               | Fermentation,                               | 1                      |          |
| Active<br>substances                | Semi-synthetic *        | Fermentation, single                        | Fermentation,<br>family                     | Peptides               | _        |






| EMA Guidel  | ine  |                                   |                                   | Pharma<br>Consulting                   | & Service |
|---|--|-----------------------------------|-----------------------------------|--|-----------|
|   | EMA guide  | •                                 | •                                 |  |           |
| (EMA  | /CHMP/CVM  | P/QWP/19                          | 9250/2009                         | corr.)                                 |           |
|   |  |                                   |                                   |  |           |
| Guideline o   | n setting specifica  | tions for relate                  | d impurities in                   | antibiotics                            |           |
|   | in section B specified                                       |                                   |                                   |  |           |
|   |  |                                   |                                   |  |           |
|   |  |                                   |                                   |  |           |
| Active<br>substances                                | Semi-synthetic *   | Fermentation, single              | Fermentation, family              | Peptides                               |           |
| Active  |  | Fermentation,                     | Fermentation,                     | 1                                      |           |
| Active<br>substances                                | Semi-synthetic *   | Fermentation, single              | Fermentation,<br>family           | Peptides                               |           |
| Active<br>substances<br>Reporting                   | Semi-synthetic *   | Fermentation,<br>single           | Fermentation,<br>family<br>0.10%  | Peptides 0.1%                          |           |
| Active<br>substances<br>Reporting<br>Identification | Semi-synthetic *           0.05%/0.03%           0.10%/0.05% | Fermentation,<br>single0.10%0.15% | Fermentation,<br>family0.10%0.15% | Peptides           0.1%           0.5% |           |
| Active<br>substances<br>Reporting<br>Identification | Semi-synthetic *           0.05%/0.03%           0.10%/0.05% | Fermentation,<br>single0.10%0.15% | Fermentation,<br>family0.10%0.15% | Peptides           0.1%           0.5% |           |





| Conseq | uences of EMA Guideline                           | Pharma<br>Consulting & Services |
|--------|---|---------------------------------|
| Ph.E   | ur. 9.8.  |                                 |
| Limi   | ts of Impurities for Amoxicillin So               | dium                            |
|        |   |                                 |
|        | $\frac{\text{Limit}}{\text{impurity J}} \leq 3\%$ |                                 |
|        | any other impurity $\leq 2\%$                     |                                 |
|        | total $\leq 9\%$                                  |                                 |
|        | disregard limit 0,1 %                             |                                 |
|        |   |                                 |
|        |   |                                 |
|        |   |                                 |




| onsequences of EMA Gui                 |                           | Consulting & Servic |
|--|---------------------------|---------------------|
| Limits according to EMA                | A Guideline               |                     |
|  | Limit                     |                     |
| Impurity J                             | <u>&lt;</u> 2.0 %         |                     |
| Impurity D (sum of isomers D1, D2)     | <u>&lt;</u> 1.5 %         |                     |
| Impurity C (sum of isomers C1, C2)     |                           |                     |
| Impurity E (sum of isomers E1, E2)     | for each impurity < 1.0 % |                     |
| Impruity G                             |                           |                     |
| Impurity K (sum of isomers K1, K2)     | <u>&lt;</u> 0.8 %         |                     |
| sum of impurities F and P              | <u>&lt;</u> 0.6 %         |                     |
| Impurity L                             | <u>&lt;</u> 0.5%          |                     |
| Impurity N                             | <u>&lt;</u> 0.4%          |                     |
| Impurities A, B, H, I, M, O, U, V      | for each impurity < 0.3 % |                     |
| Any other impurity                     | <u>&lt;</u> 0.15 %        |                     |
| Total                                  | <u>&lt;</u> 4.0 %         |                     |
| Reporting threshold                    | <u>&lt;</u> 005 %         |                     |
| - 21 impurities to be identified and o | quantified                |                     |
| 19                                     | Dr. Bernhard Wolf         | 16                  |


| Last Proposal of the Exp           | berts of Group 7               |  |
|------------------------------------|--------------------------------|--|
|                                    | Limit                          |  |
| Impurity J                         | <u>≤</u> 2.0 %                 |  |
| Impurity D (sum of isomers D1, D2) | <u>&lt;</u> 1.5 %              |  |
| Impurity C (sum of isomers C1, C2) |                                |  |
| Impurity E (sum of isomers E1, E2) | for each impurity < 1.0 %      |  |
| Impruity G                         |                                |  |
| sum of impurities F and P          | <u>&lt;</u> 0.6 %              |  |
| Impurity K, L                      | each impurity <u>&lt;</u> 0.5% |  |
| Impurity N                         | <u>&lt;</u> 0.4%               |  |
| Any other impurity                 | <u>&lt;</u> 0.30 %             |  |
| Total                              | <u>&lt;</u> 4.0 %              |  |
| Reporting threshold                | < 005 %                        |  |


















| Lost in conversion  |   |  |
|---|---|--|
| <ul> <li>Principle:         <ul> <li><u>quantity</u> of substance is <u>measured</u> in <u>mass</u></li> <li><u>potency</u> is <u>estimated</u> in <u>units</u> defined by a <u>reference standard</u></li> </ul> </li> </ul>   |   |  |
| -> potency of complex antibiotics (mixtures) cannot be measured in terms of mass  |   |  |
| <ul> <li>Definition of IU:         <ul> <li>activity contained in a given amount (mg or vial) of a particular batch of a reference standard expressed in an assay system -&gt; ≠ mass unit</li> <li>IU depends on the activity of the substance and therefore varies from substance to substance</li> </ul> </li> </ul> |   |  |
| Example: 1 <sup>st</sup> ISA for Gentamicin<br>The IU was defined in 1968 as the <u>activity</u> contained in 0.00156 mg of the<br>preparation  |   |  |
| preparation   | 1 IU $\neq$ 0.00156 mg and 1 IU $\neq$ 1.56 µg<br>but in this case 1 IU = 1"µg" of activity |  |
| -> Do not use conversion factor<br>Use the RS established for the intended purpose in the corresponding Pharmacopoeia   |   |  |
| Sylvie JORAJURIA©2019 EDQM, Council of Europe. All rights reserved.   |   |  |








| Transitioning from microbiological assay<br>to LC in Ph. Eur.   |                             |                  |                                  |     |  |  |  |
|---|-----------------------------|------------------|----------------------------------|-----|--|--|--|
| <ul> <li>Introduction of LC can be envisaged when:</li> <li>purity of antibiotic is high e.g. &gt; 90 %</li> <li>structure of the substance is known</li> <li>selective and accurate chromatographic methods are available</li> </ul> |                             |                  |                                  |     |  |  |  |
|   | Antibiotic                  | CRS for LC assay | CRS for<br>microbiological assay | ISA |  |  |  |
|   | Tobramycin                  | yes              | no                               | yes |  |  |  |
|   | Erythromycin                | yes              | yes                              | yes |  |  |  |
|   | Dihydrostreptomycin sulfate | yes              | no                               | yes |  |  |  |
|   | Netilmicin sulfate          | yes              | yes                              | yes |  |  |  |
| Sylvie JORAJURIA@2019 EDQM, Council of Europe. All rights reserved.   |                             |                  |                                  |     |  |  |  |













#### 1923 Meeting on Standards Edinburgh, 1<sup>st</sup> international meeting on standardization of biologicals

Sylvie JORAJURIA©2019 EDQM, Council of Europe. All rights reserved.

#### Stay connected with the EDQM

Thank you for your attention


EDQM Newsletter: https://go.edqm.eu/Newsletter LinkedIn: https://www.linkedin.com/company/edqm/ Twitter:@edqm\_news Facebook: @EDQMCouncil of Europe

edom

13


C








| WHERE ARE WE TODAY?   |                                |   |  |                          |                          |  |
|-----------------------|--------------------------------|---|--|--------------------------|--------------------------|--|
|                       | Ph.Eur. Cl                     | hapter 2.2.4  | 8. Rama  | an Spectroso             | сору                     |  |
| Paraceta              | amol for equip                 | ment qualificati                                      | on CRS   |                          |                          |  |
| Mataria               | ما مام برمانه الم              | un atonia a difan island                              |  |                          |                          |  |
| Materia               | al thoroughly cha              | racterised for ident                                  | ity, purity, nor   | nogeneity                |                          |  |
|                       | Table 2.2.481                  | Wavenumber shifts (and acceptable tol                 |  |                          |                          |  |
|                       |                                | Wavenumber shifts <sup>4</sup><br>[cm <sup>-1</sup> ] | Te   | Hand-held                |                          |  |
|                       | ·                              | x = x   | [cm <sup>-1</sup> ]  | [cm <sup>-1</sup> ]      |                          |  |
|                       | Polystyrene <sup>n</sup>       | 620.9   | ± 1.5  | ± 2.5                    |                          |  |
|                       |                                | 1001.4  | ± 1.5  | ± 2.0                    |                          |  |
|                       |                                | 1031.8  | ± 1.5  | ± 2.0                    |                          |  |
|                       |                                | 1602.3  | ± 1.5  | ± 3.0                    |                          |  |
|                       |                                | 3054.3  | ± 3.0  | NA <sup>z</sup>          |                          |  |
|                       | Paracetamol <sup>C</sup>       | 797.2   | ± 1.5  | ± 2.5                    |                          |  |
|                       |                                | 857.9   | ± 1.5  | ± 2.0                    |                          |  |
|                       |                                | 1168.5  | ± 1.5  | ± 2.0                    |                          |  |
|                       |                                | 1236.8  | ± 1.5  | ± 2.0                    |                          |  |
| and the second second |                                | 1323.9  | ± 1.5  | ± 2.5                    |                          |  |
|                       |                                | 1648.4  | ± 1.5  | ± 3.0                    |                          |  |
|                       |                                | 2931.1  | ± 2.0  | NA <sup>#</sup>          | Statistics in the second |  |
|                       | 011 0                          |   |  | eaon                     | COLINCE OF ELECTE        |  |
|                       |                                |   | and the second s |                          | - (2)                    |  |
| S.Almeling ©          | 03/2019 EDQM, Council of Europ | e. All rights reserved                                |  | Berthe Statistics & Con- | CONSEIL DE L'ELIKOPE     |  |










































| WHAT IS NEGLIGIBLE?   |                        |  |  |  |  |
|---|------------------------|--|--|--|--|
| Although different rules (1/3-rule to 1/5-rule) are often applied in metrology, no clear rule could be identified as regards to what can be considered "small" or "negligible".<br>Mathematically, the underestimation of the combined standard uncertainty $(u_{(x)})$ is as below, depending on the rule applied: |                        |  |  |  |  |
| Omitting an   | Underestimation of the |  |  |  |  |
| uncertainty   | combined standard      |  |  |  |  |
| contributor of:   | uncertainty:           |  |  |  |  |
| 1/3   | 5%                     |  |  |  |  |
| 1/4   | 3%                     |  |  |  |  |
| 1/5   | 2%                     |  |  |  |  |
| S.Almeling © 03/2019 EDQM, Council of Europe. All rights reserved   |                        |  |  |  |  |

٦

Г



















|     | Specific information EDQM Reference substances online database <a href="https://crs.edqm.eu/">https://crs.edqm.eu/</a> |   |   |               |  |  |  |  |
|-----|--|---|---|---------------|--|--|--|--|
|     | Available since Cat. No.   | Name                                      | Batch No.   | Unit Quantity |  |  |  |  |
|     | <u>S0100000</u>  | Salbutamol                                | 2   | 50 mg         |  |  |  |  |
|     | <u>S0150000</u>  | Salbutamol sulfate                        | 4   | 50 mg         |  |  |  |  |
|     | <u>Y0000030</u>  | Salbutamol impurity B                     | 6   | 5 mg          |  |  |  |  |
|     | Y0000031   | Salbutamol impurity F                     | 9   | 10 mg         |  |  |  |  |
| 1   | Y0000032   | Salbutamol impurity I                     | 4   | 0.006 mg      |  |  |  |  |
|     | Y0000034   | Salbutamol impurity G                     | 4   | 10 mg         |  |  |  |  |
|     | <u>Y0000071</u>  | Salbutamol impurity D                     | 6   | 10 mg         |  |  |  |  |
|     | Y0001186   | Salbutamol impurity J                     | 3   | 0.00045 mg    |  |  |  |  |
| 111 | Y0001288   | Salbutamol sulfate for system suitability | 3   | 10 mg         |  |  |  |  |
| M   | Weber @2019 EDQM, Council of Europe. All rights re-  | served.                                   | Longian Barlant<br>Kongan Barlant<br>di Kolaty<br>di Kolaty<br>ki Ko |               |  |  |  |  |



|                                       | Specific information   |
|---------------------------------------|--|
| Name                                  | Benzylpenicillin sodium  |
| Catalogue<br>code                     | 8090000  |
| Batch<br>number*                      | 8  |
| Assigned value                        | See leafiet  |
| Validity<br>Additional<br>information | Batch 8 is valid at the printing dite: 2019-2-8  |
| Storage<br>conditions<br>Safety data  | The standard is intended for immediate use.<br>Recommended EDQM storage conditions for unopened containers : +5°C ± 3°C<br>Safety Data Sheet is available from the detailed view or upon request.  |
| Leaflet                               | Click on the hyperlink to download the leaflet containing the instructions for use, <b>if available</b> (Adobe Acrobat Reader version 5 or higher, or the corresponding browser plug-in is needed to open the file) click to download the leaflet                    |
| Origin                                | Click on the hyperlink to download the origin to check if import permit is required in your country, if available (Adobe Acrobat Reader version 5 or higher, or the corresponding browser plug-in is needed to open the file) click to download Origin Of Goods, pdf |
|                                       |  |







|   | -   |                 |   |  |  |                          |                       |         |
|---|---|-----------------|---|--|--|--------------------------|-----------------------|---------|
|   | In use  |                 |   | 07/2017:0113   |  |                          |                       |         |
| Monograph Number                            | 00113   |                 |   | BENZYLPENICILLIN POTASSIUM<br>Benzylpenicillinum kalicum                         |  |                          |                       |         |
| English Name                                | Benzylpenicillin potassium  |                 |   | benzyipenicillinum kalicum   |  |                          |                       |         |
| French Name                                 | Benzylpénicilline potassique  |                 |   | The following chro   | matogram is shown for informat<br>European Pharmacoo | ion but will no<br>vonia | t be published in the |         |
| Latin Name                                  | Benzylper   | nicillinum      | kalicum   | 1  | 'П   |                          |                       |         |
| Pinyin Name                                 |   |                 |   |  |  |                          |                       |         |
| Chinese Name                                |   |                 |   |  |  |                          |                       |         |
| Pharmeuropa                                 | 24.3  |                 |   |  |  |                          |                       |         |
| Published in English Supplement             | 9.2   |                 |   |  |  |                          |                       |         |
| Published in French Supplement              | 9.2   |                 |   |  |  |                          |                       |         |
| Chromatogram                                | Available   |                 |   | J. MANIM TALL  |  |                          |                       |         |
| Additional information                      | Not available   |                 |   | o ia zo ale do da rás ele tito tito tale tele tito tele tito tele zo zito zan mm |  |                          |                       |         |
| History                                     | <u>View history</u>   |                 | 1. impurity A   | 4 and 5. isomers of impurity E   | 9. benzy   | Apenicillin              |                       |         |
| Interchangeable (ICH_Q4B)                   | NO  |                 | Impurty D     6. Impurty B     10. Impurty G     J. Impury G     J. Impurty G     J. J |  |  |                          |                       |         |
| Chapter 5.8<br>Pharmacopoeial harmonisation |   |                 |   |  |  |                          |                       |         |
|   | Available<br>since  | Cat. No.        | Name  | Batch No.  | Unit Quantity  | Price                    | SDS Produ             | ct Code |
|   |   | <u>B0700000</u> | Benzylpenicillin potassium  | 2  | 100 mg   | 79<br>EUR                |                       |         |
| Reference standards                         |   | <u>B0900000</u> | Benzylpenicillin sodium   | 8  | 200 mg   | 79<br>EUR                |                       |         |
|   |   | <u>P1100000</u> | Phenoxymethylpenicillin<br>potassium  | 4  | 250 mg   | 79<br>EUR                |                       |         |
|   |   | <u>Y0001889</u> | Benzylpenicillin for system<br>suitability  | 1  | 10 mg  | 79<br>EUR                |                       |         |
|   | Test(s) Brand Name/Information  |                 |   |  |  |                          |                       |         |
| Practical Information                       | Related From 9.2: YMC Pack-Pro is suitable. D0 ( dwell volume used for development of the |                 |   |  |  |                          |                       |         |
|   | Assay   | From            | 9.2: Waters Atlantis T3 is su   | uitable  |  |                          |                       |         |



## 🔈 Interesting questions

# Can I use compendial reference standards for method validation or stability studies?

Compendial reference standards are established for the intended use in the correponding monograph(s). The required information is provided in the accompanying leaflet.

The use of compendial reference standards for other purposes is within the reponsibility and justification of the user, not because they are unsuitable, but because we cannot know the specific requirements beyond the monograph.

For example, the availability of the same batch of a reference standard for the duration of a stability study should not be assumed.

[Note: Please see Ph. Eur. Chapter 5.12 Section 3 on the conditions for the use of Ph. Eur. reference standards with an assigned content for determination of content/potency in pharmaceutical preparations.]

## Interesting questions

# How can we establish a traceable in-house standard?

For qualitative reference standards, it is possible to prepare an inhouse standard traceable to the compendial reference standard.

However, for quantitative in-house standards this is more difficult because the uncertainty of the value of the compendial reference standard is not needed for the intended use in the corresponding monograph and so it is not given (see Ph. Eur. Chapter 1.4 General Notices Sub-section Limits).

A suitable approach would be to establish a primary in-house standard thouroughly characterised, and verified against the compendial ref. standard.




# What is the validity of a compendial reference standard?

Compendial reference standards do not come with an expiry date, however their validity is provided to users.

A re-test programme is established and implemented to ensure the continued fitness-for-use of the European Pharmacopoeia reference standards.

The user can document the suitability of the CRS batch at the time of use via our online reference standard database, where a batch-validity-statement (BVS) is available for printing.








How do you assign the content of your reference standards? And what is meant by content 'as is' ?


Quantitative reference standards are tested for the relevant requirements of the correponding monograph(s). Furthermore, water, residual solvents, loss on drying, related substances and inorganic impurities are quantified (mass-balance).

The obtained content is verified by independent methods (e.g. qNMR, DSC, titration, elemental analysis).

The content assigned is 'as is'. Therefore, do not dry or desiccate the reference standard before use. Allow the closed container to equilibrate at ambient conditions before opening to avoid uptake (or loss) of moisture.








#### Agenda

#### **Topics**

- Example Questions
- Resources / References




# <section-header><section-header><section-header><section-header><section-header><list-item><list-item><list-item><list-item><list-item>


## **Example Question - 2**





#### Basis for Use / Handling Conditions


- Label states on how to use and must be followed
- Assigned Label value (typically mg/mg) for quantitative standards should be taken into account
- "As Is" basis is the preferred approach if supported by the results
- Handling conditions are added for example use at NMT 40%RH or between 20 and 40% RH
- Additional details, if applicable, are included in the Certificate
- Determine water content or loss on drying at the time of use

















### **Become a USP Volunteer Expert**

- Impact global public health
- > Share expertise and collaborate with colleagues worldwide
- Add distinction to your career

Currently looking for volunteering candidates with experience in:

- > Development and characterization of reference standards
- Metrology and ISO reference standards guidelines
- Chemical medicines, excipients, biologics, and dietary supplements

Visit: http://www.usp.org/about/volunteer-experts

